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Global Tuberculosis
Perspectives, Prospects, and Priorities
Despite being nearly 100% curable, tuberculosis re-
mains a major public health problem, representing the
second leading cause of death from infectious diseases
globally, with drug-resistant tuberculosis increasingly
common. In 2012, an estimated 8.6 million people
developed tuberculosis worldwide—a global incidence
rate of 122 persons per 100000 population—and 1.3
million people died. Incidence rates vary from high in
southern Africa (550/100000 population in Mozam-
biqueandZimbabweand 1000/100000population in
South Africa) to fewer than 10/100000 population in
theUnitedStates,Canada,andmostofWesternEurope.1
Althoughtheglobalprevalenceofmultidrug-resistant tu-
berculosis was estimated at 3.6% of newly diagnosed
and 20.2% of previously treated patients, these rates
were 20% to 35% for newly diagnosed cases and 50%
to 69% for retreatment cases in the Russian Federa-
tion and some other former Soviet republics.
In sub-Saharan Africa, the tuberculosis epidemic is
drivenbyHIV throughboth increased reactivationof la-
tent tuberculosis infectionandthe increasedriskof rapid
development of disease soon after exposure toMyco-
bacterium tuberculosis because of HIV-induced immu-
nodeficiency. There is lower tuberculosis incidence in
Asia,butbecauseAsia’spopulation issomuch larger than
Africa’s—more than 4 billion compared with about a
billion—75%of the5million tuberculosis cases in the22
highest-burden countries are in Asia. In these coun-
tries, crowding, poverty, and inadequate tuberculosis
treatmentcompletionratescontribute to theepidemic.2
Despite these statistics, marked progress has oc-
curred since theWorld Health Organization (WHO) de-
clared tuberculosis a global emergency20years ago. In
1995, fewer than 2 million patients were successfully
treated using theWHO’s Directly Observed Treatment,
short course (DOTS) strategy, less than a quarter of the
estimated total; by 2011, nearly 5 million patients were
treated successfully with DOTS. Approximately 56mil-
lionpatients havebeen treated successfully since 1995,
preventinganestimated22milliondeaths.However,ev-
ery year about 3 million people with tuberculosis are
missed by health systems. Mortality rates are declin-
ing, albeit slowly, in all regions of theworld. Since 1990,
the death rate associated with tuberculosis has de-
creased 45%, from 25 persons to 14/100000 popula-
tion, although rates vary widely between countries.
The greatest risk to tuberculosis control is lack of
implementationofeffectiveandcurrentlyavailablestrat-
egies and tools. Tuberculosis control rests on 3 funda-
mental principles: prompt and accurate diagnosis, ef-
fective treatment begun immediately upon diagnosis
and monitored until completion, and interruption of
transmission.
Diagnosis
Microbiological examinationof sputumsmears for acid-
fast bacilli, despite limitations, remains themainstay of
diagnosis. Newer diagnostics provide greater sensitiv-
ity, particularly amongchildrenandpersonswithHIV in-
fection (whose sputumsmears areoftennegative), and
canalso identify rifampin resistance. Thesenewer tests
canenhance,butnot yet replace, smearmicroscopybe-
cause of expense and requirements for suitable infra-
structure, including stableelectricity supplies. Early and
accurate identification of tuberculosis can result in ear-
lier treatment and decrease transmission, but only if
treatment is promptly initiated.3
Rapid and Complete Treatment
All patients diagnosed with tuberculosis should receive
prompt, complete, and effective treatment. In practice,
however, asmany as 10% to 30%of patients with labo-
ratory-detected smear-positive sputum do not start
treatment,4 the result ofdisconnectsbetween laborato-
ries, treating facilities, andpatients.Turnaroundtimebe-
tween identification of a positive specimen, whether by
smear microscopy or molecular diagnostics, and treat-
ment initiationshouldnotbe longer than24hours.Com-
municationbetweendiagnosingandtreating facilities re-
mainsproblematic,andresponsibilityforpromptlyfinding
patients once there is a positive result remains nebulous
inmany programs.5
Monitoringandevaluationofthediagnosisandtreat-
mentcascadewithinevery facility shouldbe routineand
performedquarterly, but in practice it is rare for a treat-
ing facility to know what percentage of patients diag-
nosed actually began treatment at the facility to which
theywere referred,orhave informationaboutoutcomes
of thesediagnosedpatients, such as cured, died, lost to
follow-up, or remaining smear- or culture-positive.
Effective, regular, and structured supervisionof tu-
berculosis diagnostic and treatment facilities and their
patients, combined with program management and
evaluation, is essential to tuberculosis control. Supervi-
sionhelpsdeterminewhypatientsdonot seek care and
how attendance might be improved and teaches staff
how to perform essential tasks and keep accurate rec-
ords. Cohort analysis, performedquarterly andanswer-
ing 2 simple questions: how many patients were diag-
nosedwith tuberculosis andwhat happened to them is
thehallmarkofeffectivetuberculosiscontrolandamodel
of accountability for treatment of any chronic illness.
Supportivesupervision—helpinghealthworkers im-
prove their performance—requires staff trained in spe-
cific skills,withcentral orprovincial staff supervisingdis-
trict officerswho in turn supervise frontlinehealth staff.
Regular, structured field visits to treatment clinics en-
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able supervisory staff to review information in registers and treat-
ment records and interview patients and health care workers and
are essential to improve performance.
A specializedcentral unit toprovide leadership, training, super-
vision, data analysis, evaluation, reporting, and accurate drug fore-
casting so thatmedicationsnever runout in any clinic is essential to
maintain treatment completion rates as close to 100%as possible.
Because a central unit is responsible for countrywide tuberculosis
control, such a structure cannot be construed as either inefficient
or inappropriate “verticalization.” Although there have beenmajor
increasesglobally in tuberculosis-control funding, consistent finan-
cial support for program management and supervision is often
insufficient.
There is ongoing debate about the need for direct observation
of treatment.Althoughtreatmentobservation isoftenofficialpolicy,
it is difficult to implementwell and frequently not actually practiced.
Randomized clinical trials are the gold standard to evaluatedifferent
pharmacological treatments and may provide important informa-
tionondifferentprogramdesigns, butmaynotaccurately assess the
valueof treatmentobservation.6A2007meta-analysispurportingto
show that self-administered treatment is as good as direct observa-
tionoftreatment included5randomizedclinical trials.7However,none
of these trials includeddata on long-termoutcomes such as relapse,
additional spreadof tuberculosis,ordevelopmentandspreadofdrug
resistance, all of which are crucial outcomes to evaluate, and rel-
evance to national program scale-up could not be assessed.
Effective treatmentobservation is anactivity thatbuilds,main-
tains, andstrengthens thebondbetween thepatient and thehealth
careworker, ensuring that the patient is the center of the program,
thereby increasing the likelihood of cure. It is the concrete expres-
sion of the program’s acceptance of responsibility—if the patient
stops treatment, the programwill expend resources to reengage.
Infection Control
In low-resourcesettingswithhighHIVprevalenceandopen,crowded
hospital wards, substantial transmission of tuberculosis is likely; in
southernAfrica,devastatingand lethaloutbreaksofextensivelydrug-
resistant tuberculosis have occurred. Within hospitals, the sim-
plest ways to reduce tuberculosis spread are often themost effec-
tiveand leastexpensive—but the leastused.These include increasing
the index of suspicion and ensuring that patients who may have
tuberculosis are separated fromothers and tested rapidly, separat-
ing patientswith suspected drug-resistant tuberculosis fromother
tuberculosis patients, ensuring that windows remain open, adding
windowsandskylights,andconstructingoutdoorwaitingareaswhen
possible.Healthcareworkersareat considerable risk, yet fewhealth
care systems in high tuberculosis incidence areasmonitor tubercu-
losis amongstaff, andevenwhen theydo, follow-uphasbeenpoor.8
Drug-Resistant Tuberculosis
The increase in patients who require treatment for drug-resistant
tuberculosis is a symptomof 2 different problems: lack of infection
controlwithin congregate settings, suchashealth care facilities and
prisons,which leads toprimarydrugresistance;and inadequatecure
rates, particularly of patients who are smear-positive, which leads
to acquired drug resistance.
Promptdiagnosis andeffective treatmentofpatientswithdrug-
resistant tuberculosis is essential, especially in areas with high HIV
prevalence. Molecular testing will improve diagnosis, but effective
treatmentdependsondrugsusceptibility testing. Ideally, all patients
with tuberculosis, or at least thosewho have not responded to prior
treatment, should have isolates tested for drug resistance. Treat-
ment of drug-resistant tuberculosis is imperative, but requires staff
training and supervision. Second-line drugs are, excepting the
fluoroquinolones, less effective andmore toxic than first-line drugs,
and farmore costly. Increased resources arenecessary, butmust not
be diverted from existing resources for core tuberculosis control.
Conclusions
Forgetting is thekeychallenge in tuberculosis control. Political lead-
ers forget thepoor anddisenfranchised,whoaremost likely to con-
tract and die of tuberculosis. Health leaders forget simple, low-
technology interventions and therefore neglect the core work of
treatmentobservation, fieldsupervision,andcohortmonitoringand
evaluation. Patients forget how sick theywere andmay stopmedi-
cations when symptoms subside.
The hallmark of tuberculosis is persistence—the persistence of
Mtuberculosis for life inmost infectedpeople andpersistenceof re-
producingbacilli during the initialweeksof treatment. Thismustbe
matched by persistence with basic tuberculosis control principles,
not just in planning but in actual implementation. Innovation in
tuberculosiscontrolprograms iscrucial, andnewtechnologycanand
should be appropriately used, but must accompany effective core
public health practice.
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